UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported)
August 30, 2007
AURIGA LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 000-26013 | 84-1334687 |
(State of incorporation) |
(Commission File Number) |
(I.R.S. EmployerIdentification No.) |
| | | |
10635 Santa Monica Blvd. #120 Los Angeles, California | 90025 |
(Address of principal executive offices) |
(Zip Code) |
| | |
| (310) 461-3600 |
(Registrant’s telephone number, including area code) |
| |
| Not Applicable |
(Former name or former address, if changed since last report) |
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): |
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| |
SECTION 8—OTHER EVENTS
Item 8.01. Other Items
On August 30, 2007, Auriga Laboratories, Inc. (the “Company”) issued a press release announcing that Philip S. Pesin, the Company’s Chief Executive Officer, has terminated his pre-arranged stock trading plan on August 30, 2007. No further sales under the plan will occur after the planned third quarter sales. These stock trading plans had previously been adopted pursuant to Securities and Exchange Commission Rule 10b5-1. A copy of that press release is furnished as an exhibit to this report as Exhibit 99.1 and is incorporated herein by reference.
The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under such section, nor shall it be deemed incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing. The Company has posted a copy of this Current Report on Form 8-K on its website at www.aurigalabs.com.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. The following exhibits are filed herewith:
Exhibit Number | | Document |
| 99.1 | | Press Release of Auriga Laboratories, Inc. dated August 30, 2007. |
| | | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | |
| | Auriga Laboratories, Inc. |
|
|
|
| Date: August 30, 2007 | By: | /s/ Philip S. Pesin |
| |
Philip S. Pesin |
| | Chief Executive Officer |
